戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 salvage enzymes that convert nicotinamide to nicotinic acid.
2 at T41 and F124 affect the interactions with nicotinic acid.
3 er assayed for PGD(2) release in response to nicotinic acid.
4 able to release PGD(2) upon stimulation with nicotinic acid.
5 nd the characteristic side-effect profile of nicotinic acid.
6  (NAAD) as a cosubstrate and is inhibited by nicotinic acid.
7 een regression of atherosclerosis and use of nicotinic acid.
8 nc1 is a nicotinamidase that converts NAM to nicotinic acid.
9  the sleep and thermoregulatory responses of nicotinic acid.
10 -the-counter niacin that do not contain free nicotinic acid.
11  known to be auxotrophic for nicotinamide or nicotinic acid.
12 rs a (SCS)Ni(II) pincer complex derived from nicotinic acid.
13 s that led to increased NAMN production from nicotinic acid.
14 unmodified polar isosteres of pyrazinoic and nicotinic acids.
15 le the hepatic glucose load), and peripheral nicotinic acid (1.5 mg.kg(-1).min(-1)) were infused.
16 repared by reacting 2-trifluoromethyl-4-iodo-nicotinic acid (2) with amidine 9a catalyzed by Pd(2)(db
17 2,4-dioxo-1,3,7-tria zaspiro-[4.4]nonan-7-yl)nicotinic acid (2e) was selected to advance into clinica
18 onicotinic acid was discovered to afford the nicotinic acid 3.
19                                              Nicotinic Acid 400 mg lowered ejection fraction by 4% (6
20 unctionalized substituents introduced at the nicotinic acid 5-position are recognized by the sea urch
21   The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2-furyl]methylene-hydr
22 , some amino acids, thymidine, trigonelline, nicotinic acid, 5,6-dihydrouracil, hesanal, cis-olefin,
23                    Similarly, treatment with nicotinic acid, a lipolysis inhibitor, restored insulin-
24 mophila differentiation is also triggered by nicotinic acid, a precursor of the central metabolite NA
25 se domain to supply ammonia for amidation of nicotinic acid adenine dinucleotide (NaAD(+)) to NAD(+).
26 hat LarB carboxylates the pyridinium ring of nicotinic acid adenine dinucleotide (NaAD) and cleaves t
27 a mutant that deacetylates peptides by using nicotinic acid adenine dinucleotide (NAAD) as a cosubstr
28 ide phosphate (NADP(+) ) for the NA group of nicotinic acid adenine dinucleotide (NAAD) inside endoly
29 last step of NAD(+) biosynthesis, converting nicotinic acid adenine dinucleotide (NaAD) to NAD(+) Som
30                          We also report that nicotinic acid adenine dinucleotide (NAAD), which was no
31 xtracts of HeLa cells, NAADP was degraded to nicotinic acid adenine dinucleotide (NAAD).
32          Markers of increased NAD+ synthesis-nicotinic acid adenine dinucleotide and methyl nicotinam
33  metabolites by phosphorylating nicotinamide/nicotinic acid adenine dinucleotide at the adenosine 3'-
34 tinic acid and metabolize exogenous NAADP to nicotinic acid adenine dinucleotide by a 2'-phosphatase.
35     Both products of AvrRxo1, 3'-NADP and 3'-nicotinic acid adenine dinucleotide phosphate (3'-NAADP)
36 synthesized and characterized [(32)P-5-azido]nicotinic acid adenine dinucleotide phosphate ([(32)P-5N
37 duce adenosine diphosphate ribose (ADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP(+))
38  we identify the Ca(2+)-mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) an
39                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) an
40 -pore channel blocker NED-19 (1 mum) and the nicotinic acid adenine dinucleotide phosphate (NAADP) an
41 rt that although Ca(2+) increases induced by nicotinic acid adenine dinucleotide phosphate (NAADP) ar
42 ncreatic acinar nuclei could be activated by nicotinic acid adenine dinucleotide phosphate (NAADP) as
43 arterial smooth muscle cells have shown that nicotinic acid adenine dinucleotide phosphate (NAADP) ev
44  nicotinamide adenine dinucleotide (NAD) and nicotinic acid adenine dinucleotide phosphate (NAADP) fr
45                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) ha
46 ch to detecting the calcium second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) in
47             Accumulating evidence implicates nicotinic acid adenine dinucleotide phosphate (NAADP) in
48 +)](i) via the novel Ca(2+)-mobilizing agent nicotinic acid adenine dinucleotide phosphate (NAADP) in
49  We show here that intracellular dialysis of nicotinic acid adenine dinucleotide phosphate (NAADP) in
50                We investigated the effect of nicotinic acid adenine dinucleotide phosphate (NAADP) in
51                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
52                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
53                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
54                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
55                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
56 izing messengers described, the most potent, nicotinic acid adenine dinucleotide phosphate (NAADP) is
57                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
58                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
59                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
60                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
61                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
62                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
63                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
64                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
65                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
66                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) is
67                The measurement of changes in nicotinic acid adenine dinucleotide phosphate (NAADP) le
68                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) mo
69 el intracellular Ca(2+)-mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) on
70     In sea urchin eggs, Ca2+ mobilization by nicotinic acid adenine dinucleotide phosphate (NAADP) po
71                                              Nicotinic acid adenine dinucleotide phosphate (NAADP) po
72                         The second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) re
73 have shown that cyclic ADPribose (cADPr) and nicotinic acid adenine dinucleotide phosphate (NAADP) re
74                It was reported recently that nicotinic acid adenine dinucleotide phosphate (NAADP) re
75 ond messengers cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) st
76                                              Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) st
77                                 Analogues of nicotinic acid adenine dinucleotide phosphate (NAADP) wi
78    In this study, we compared the effects of nicotinic acid adenine dinucleotide phosphate (NAADP), a
79                                              Nicotinic acid adenine dinucleotide phosphate (NAADP), a
80 n channels previously thought to be gated by nicotinic acid adenine dinucleotide phosphate (NAADP), a
81        The putative intracellular messenger, nicotinic acid adenine dinucleotide phosphate (NAADP), r
82                                              Nicotinic acid adenine dinucleotide phosphate (NAADP), t
83 s (TPC2) are lysosomal proteins required for nicotinic acid adenine dinucleotide phosphate (NAADP)-ev
84                                              Nicotinic acid adenine dinucleotide phosphate (NAADP)-ev
85        We have examined the possible role of nicotinic acid adenine dinucleotide phosphate (NAADP)-me
86 m release triggered by the second messenger, nicotinic acid adenine dinucleotide phosphate (NAADP).
87 isphosphate (InsP(3)), cyclic ADP ribose and nicotinic acid adenine dinucleotide phosphate (NAADP).
88 se Ca2+ from intracellular stores, including nicotinic acid adenine dinucleotide phosphate (NAADP).
89 +) messengers, cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP).
90  regulation by inositol 1,4,5-trisphosphate, nicotinic acid adenine dinucleotide phosphate and cyclic
91 ositol trisphosphate, cyclic ADP ribose, and nicotinic acid adenine dinucleotide phosphate with disti
92 , little is known about Ca2+ mobilization by nicotinic acid adenine dinucleotide phosphate, a pyridin
93 cto-enzymes to produce cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate, and/or ma
94 llular messengers include cyclic ADP ribose, nicotinic acid adenine dinucleotide phosphate, arachidon
95 e-targeted calcium release channels gated by nicotinic acid adenine dinucleotide phosphate, as also a
96 -releasing messengers, cyclic ADP ribose and nicotinic acid adenine dinucleotide phosphate, in initia
97  the ryanodine receptor, or the receptor for nicotinic acid adenine dinucleotide phosphate.
98                     NAD+ synthetase converts nicotinic acid adenine dinucleotide to NAD+ via an adeny
99 ic NAD+ synthetases use glutamine to amidate nicotinic acid adenine dinucleotide while many purified
100 ases the myocardial levels of 3 metabolites, nicotinic acid adenine dinucleotide, methylnicotinamide,
101 tructurally related nucleotides such as NAD, nicotinic acid adenine dinucleotide, nicotinamide mononu
102                                              Nicotinic acid adenine dinucleotide-phosphate (NAADP), a
103 t of the potent Ca(2+) mobilizing messenger, nicotinic acid adenine-dinucleotide phosphate (NAADP), a
104 e CD38-derived Ca(2+) mobilizing metabolite, nicotinic acid-adenine dinucleotide phosphate (NAADP), a
105 dition, our results support a novel role for nicotinic acid-adenine dinucleotide phosphate in cannabi
106 ced calcium increase was reduced by blocking nicotinic acid-adenine dinucleotide phosphate- or inosit
107 A3 stored Ca(2+) is exclusively mobilized by nicotinic acid adenosine dinucleotide-phosphate (NAADP):
108 es in the elucidation of mechanisms by which nicotinic acid affects the lipoprotein profile and, more
109          In addition, we have found that two nicotinic acid aldehydes induce a significant conformati
110 ed reduced cutaneous flushing in response to nicotinic acid, although the improvement in serum free f
111 silencing defect only on medium deficient in nicotinic acid, an NAD(+) precursor.
112 PGD(2) release, whereas isonicotinic acid, a nicotinic acid analog with low affinity for GPR109A, had
113 -ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B(3).
114 system in which nicotinamide is converted to nicotinic acid and ammonia by nicotinamidase.
115 ve substituted at both the 5-position of the nicotinic acid and at the 8-adenosyl position was also r
116  nadC in B. bronchiseptica was influenced by nicotinic acid and by a NadQ family transcriptional repr
117  evolution of acrylamide (AA), trigonelline, nicotinic acid and caffeoylquinic acids contents (determ
118  positively regulated by the availability of nicotinic acid and glucose.
119  designated AtNIC1, converts nicotinamide to nicotinic acid and has a Km value of 118 +/- 17 microM a
120 tor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, a
121       Immediate-release niacin contains free nicotinic acid and is the least expensive form of over-t
122 ADP by base exchange from exogenous NADP and nicotinic acid and metabolize exogenous NAADP to nicotin
123                                              Nicotinic acid and nicotinamide were defined as the vita
124 ct and superior pharmacokinetics to those of nicotinic acid and nicotinamide.
125 d that may be a common architecture for both nicotinic acid and quinolinic acid (QA) phosphoribosyltr
126 s of over-the-counter niacin contain no free nicotinic acid and should not be used to treat dyslipide
127 e case in B. pertussis, the known modulators nicotinic acid and sulfate, which silence Bvg-activated
128 ired to explore the 'pleiotropic' effects of nicotinic acid and will ultimately provide a platform fo
129 han 20 mg of daily niacin, which consists of nicotinic acid and/or nicotinamide, there is growing evi
130 eled precursors tryptophan, quinolinic acid, nicotinic acid, and nicotinamide were added to the media
131 riginate from tryptophan (or aspartic acid), nicotinic acid, and nicotinamide, respectively, and conv
132 ic acid; 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid], and diclofenac [2-(2-(2,6-dichloropheny
133 related to the consumption of peas (N-methyl nicotinic acid), apples (rhamnitol), and onions (N-acety
134 ls in (0.01, 0.05, 0.09 and 0.13) mol kg(-1) nicotinic acid((aq)) (vitamin B3) solutions have been in
135  have been recorded in 1 x 10(-4) mol kg(-1) nicotinic acid((aq)) solutions.
136                   The therapeutic actions of nicotinic acid are mediated by GPR109A, a Gi protein-cou
137                         Endogenous levels of nicotinic acid are too low to significantly impact recep
138 s predominantly use nicotinamide rather than nicotinic acid as a precursor for NAD biosynthesis.
139  L. pneumophila from toxic concentrations of nicotinic acid as judged by analyzing the growth of the
140                             Nicotinamide and nicotinic acid as well as nicotinamide riboside (NR) and
141 hese observations explain the characteristic nicotinic acid auxotrophy of Shigella organisms and are
142               The most primitive pathway for nicotinic acid biosynthesis is the reaction of aspartic
143 fects in the activation of genes involved in nicotinic acid biosynthesis, cell wall integrity, and ot
144 of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD2.
145 unter sustained-release niacin contains free nicotinic acid, but some brands are hepatotoxic.
146  cost of therapy (at 2000 mg/d) and the free nicotinic acid content (quantified by high-performance l
147                                         Like nicotinic acid, (D)-beta-OHB inhibits mouse adipocyte li
148                      We hypothesize that the nicotinic acid derivative acipimox, an NAD(+) precursor,
149 eptor (PPAR) gamma agonist, pioglitazone and nicotinic acid derivatives may contribute beyond statin
150 increased as the N-alkyl chain length of the nicotinic acid derivatizing agent was increased from 1 t
151 improved by a more stable but still reactive nicotinic acid-derived tetrazine and by changing the key
152 ion of nicotinamide, a conversion product of nicotinic acid, did not affect sleep amounts and body te
153 inic acid mononucleotide (NaMN) precursor to nicotinic acid dinucleotide (NaAD) followed by its amida
154 nicotinic acid mononucleotide (NaMN) to form nicotinic acid dinucleotide (NaAD).
155 peritoneal and oral gavage administration of nicotinic acid elicited robust increases in non-rapid-ey
156  sequence for the synthesis of various 6-oxo nicotinic acid esters is described.
157        The exact cellular mechanism by which nicotinic acid exerts its antilipolytic effects has not
158                                              Nicotinic acid, fibrates, statins, and thiazolidinedione
159 4)U, the iscS(-) strain requires thiamin and nicotinic acid for growth in minimal media.
160              Surprisingly, however, omitting nicotinic acid from the growth medium, which reduces cel
161 C1 was completely dependent on the import of nicotinic acid from the growth medium.
162 of the enzyme bound to a substrate analogue, nicotinic acid, from three crystal forms at resolutions
163                  Suppression of lipolysis by nicotinic acid gives rise to a prominent rebound and the
164                                              Nicotinic acid has been used for decades for its antiath
165                                              Nicotinic acid has long been used for the treatment of d
166 in-coupled receptor 109A as the receptor for nicotinic acid has provided insights into how treatment
167 in humans; PUMA-G in mice) as a receptor for nicotinic acid has provided the opportunity to gain grea
168                 Our results suggest that the nicotinic acid-HCA2 axis is a novel negative regulator o
169 ing the nonsteroidal anti-inflammatory drugs nicotinic acid (Hnic) and its isomer isonicotinic acid (
170 , while the less potent antitubercular agent nicotinic acid hydrazide produced the corresponding nico
171 dy-state level of radicals was produced from nicotinic acid hydrazide.
172 ulated hLC-Ls released PGD(2) in response to nicotinic acid in a dose-dependant manner (effector conc
173 ls: with (NA+) and without (NA-) infusion of nicotinic acid in nine individuals with poorly controlle
174  novel role of HCA2 (GPR109A) and its ligand nicotinic acid in regulating macrophage function.
175 erved, which was significantly suppressed by nicotinic acid in wild-type BMMs (P<0.04) but not in Hca
176 methacin completely abolished the effects of nicotinic acid indicating that prostaglandins play a key
177  confirmed the involvement of GPR109A in the nicotinic acid-induced flushing response, a common side
178 and the adaptor proteins, beta-arrestins, in nicotinic acid-induced signaling and physiological respo
179 scriptional profile analysis determined that nicotinic acid induces the expression of a panel of gene
180                                    Moreover, nicotinic acid inhibited de novo NAD(+) synthesis throug
181                                     In mice, nicotinic acid inhibits lipolysis via PUMA-G, a Gi/o-cou
182                                              Nicotinic acid is a high affinity ligand, but the endoge
183                                              Nicotinic acid is an effective treatment for dyslipidemi
184                                              Nicotinic acid is one of the most effective agents for b
185 thalpy of the OHN LBHB formed in crystalline nicotinic acid is only 7.7+/-0.5 kcal mol(-1) , suggesti
186                                              Nicotinic acid is required by most isolates of Salmonell
187                                              Nicotinic acid is the most potent treatment clinically a
188                                              Nicotinic acid is the only drug that primarily lowers co
189 r NAD(+) precursors, such as nicotinamide or nicotinic acid, is dispensable.
190 P)H were in the same position as that of the nicotinic acid ligand, its C4 atom would be optimally po
191                   These results suggest that nicotinic acid mediates its flushing side effect by inte
192 her the 4- or the 5-position position of the nicotinic acid moiety have been synthesized from NADP en
193 6',2'':6'',2'''-quaterpyridines containing a nicotinic acid moiety.
194           The nadD gene, encoding the enzyme nicotinic acid mononucleotide (NaMN) adenylyltransferase
195 HO pathway responds to depletion of cellular nicotinic acid mononucleotide (NaMN) and mediates nicoti
196 onucleotides nicotinamide mononucleotide and nicotinic acid mononucleotide (NAMN) and thus catalyze N
197 sis, which catalyze the adenylylation of the nicotinic acid mononucleotide (NaMN) precursor to nicoti
198  the transfer of an adenylyl group of ATP to nicotinic acid mononucleotide (NaMN) to form nicotinic a
199 s of the two MtNadD substrates, i.e. ATP and nicotinic acid mononucleotide (NaMN).
200    This control operates at the level of the nicotinic acid mononucleotide adenylyl-transferase Nma1
201                                    Bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNA
202 oribosyltransferase (Nampt) and nicotinamide/nicotinic acid mononucleotide adenylyltransferase (Nmnat
203             Increased levels of nicotinamide/nicotinic acid mononucleotide adenylyltransferase (NMNAT
204 y either route 2 or route 3 is deamidated to nicotinic acid mononucleotide and converted to NAD by th
205 more, two novel deamidation steps leading to nicotinic acid mononucleotide and nicotinic acid ribosid
206                                            A nicotinic acid mononucleotide derivative is tethered to
207 e the substrates of these enzymes, including nicotinic acid mononucleotide, nicotinamide mononucleoti
208 osynthesis, that all anabolism flows through nicotinic acid mononucleotide, was challenged experiment
209 6 gene, a homolog of E. coli gene nadD, is a nicotinic acid mononucleotide-preferring adenylyltransfe
210  nicotinamide, respectively, and converge on nicotinic acid mononucleotide.
211 ased slowly; 2) during 4 h (from 16-20 h) of nicotinic acid (NA) administration (fasting plus NA), wh
212 1778-induced ROS can be diminished by adding nicotinic acid (NA) in a NA phosphoribosyltransferase 1
213                                              Nicotinic acid (NA) is commonly used to treat dyslipidem
214  We hypothesized that nicotinamide (NAM) and nicotinic acid (NA) modulate macrophage function to rest
215 hat the inducing signal is the limitation of nicotinic acid (NA), a precursor of nicotinamide adenine
216                          Here we report that nicotinic acid (NA), an essential vitamin, inhibits glio
217 wo enzymes that sequentially convert NAD+ to nicotinic acid (NA), are up-regulated during CR.
218 ty toward the normally inactive QA analogue, nicotinic acid (NA), indicating roles for these residues
219 (+) to be synthesized from three compounds - nicotinic acid (NA), nicotinamide (NAM) and nicotinamide
220 iae, the nicotinamidase Pnc1 converts NAM to nicotinic acid (NA), which is then used as a substrate b
221 c pH and a nonphysiological concentration of nicotinic acid (NA).
222                                              Nicotinic acid (NA, a.k.a. vitamin B3 or niacin) can red
223                     During period 2, saline (nicotinic acid [NA], n = 7), lipid emulsion (NA plus lip
224                          We report here that nicotinic acid (NAc) and its metabolic precursor, quinol
225 thyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino)nicotinic acid (NEt-TMN) were synthesized and assessed f
226 nt was with the adenylate cyclase inhibitors nicotinic acid (NIC-A), 2',3'-dideoxyadenosine (DDA), or
227 (CYS); (ii) the adenylate cyclase inhibitors nicotinic acid (NIC-A), 2',3'dideoxyadenosine (DDA), or
228 m multiple precursors, including tryptophan, nicotinic acid, nicotinamide, and nicotinamide riboside
229 etic and/or ligand activities of tryptophan, nicotinic acid, nicotinamide, and the newly identified N
230          Attachment of charged groups to the nicotinic acid of NAADP is associated with loss of activ
231 o be the molecular target for the actions of nicotinic acid on adipose tissue, and in this issue of t
232 de that the differential activity of NAM and nicotinic acid on infected macrophages suggests host-spe
233  effects of acute systemic administration of nicotinic acid on sleep in mice.
234 icotinamide riboside uptake without altering nicotinic acid or nicotinamide import.
235                                              Nicotinic acid, or its analogues, seems to alleviate ins
236 tes with the NAD(+) precursors nicotinamide, nicotinic acid, or nicotinamide mononucleotide, the Ca(2
237 alvage" pathways starting from nicotinamide, nicotinic acid, or nicotinamide riboside (NR).
238 e dinucleotide, nicotinamide mononucleotide, nicotinic acid, or nicotinamide.
239                     The broad utility of the nicotinic acid pathway to couple central metabolism and
240 o-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243), a known hERG channel activat
241 o-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid [PD307243 (PD)] and 1,3-bis-(2-hydroxy-5-
242 for dyslipidemia, oral doses of 1-3 grams of nicotinic acid per day lower serum triglycerides, raise
243 , flufuran, gregatin B, hydroxysydonic acid, nicotinic acid, phomaligin A, spinulosin and terrein.
244  nicotinamide phosphoribosyl transferase and nicotinic acid phosphoribosyl transferase showed moderat
245  genome and promotes epigenetic silencing of nicotinic acid phosphoribosyltransferase (NAPRT), a key
246              Here, we show the gene encoding nicotinic acid phosphoribosyltransferase (NAPRT), a seco
247 udomonas, which is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some Ps
248                                 Two putative nicotinic acid phosphoribosyltransferases, PncB1 (Rv1330
249 In addition to hydrolyzing nicotinamide into nicotinic acid, PncA also hydrolyzes the prodrug pyrazin
250                   In addition, we found that nicotinic acid promoted the binding of beta-arrestin1 to
251 esirable and undesirable clinical actions of nicotinic acid raises interesting questions regarding th
252                                              Nicotinic acid receptor (GPR109A) gene expression was as
253 ery and characterization of a membrane-bound nicotinic acid receptor (HM74) explains niacin's acute i
254 es in carbohydrate metabolism induced by the nicotinic acid receptor agonist, Acipimox, using hyperpo
255                                              Nicotinic acid receptor agonists have previously been sh
256           In conclusion, we demonstrate that nicotinic acid receptor agonists impair cardiac contract
257           The human ortholog HM74a is also a nicotinic acid receptor and likely has a similar role in
258  targeting the beta-adrenergic receptors and nicotinic acid receptor GPR109a highlight the powerful c
259  monomethyl fumarate, another agonist of the nicotinic acid receptor GPR109A, fully recapitulated the
260           Research on signalling through the nicotinic acid receptor might give rise to novel and mor
261                               Treatment with nicotinic acid reduced nuclear factor kappaB (NF-kappaB)
262                                              Nicotinic acid remains the most effective therapeutic ag
263                       Treatment with 300 muM nicotinic acid (reported EC50 3 muM, peak plasma concent
264 es pncA and pncB, for use of nicotinamide or nicotinic acid, respectively, for NAD synthesis.
265        Substitution at the 4-position of the nicotinic acid resulted in the loss of agonist potency f
266 id as well as nicotinamide riboside (NR) and nicotinic acid riboside (NAR) are the major precursors f
267 Here, we show that nicotinamide riboside and nicotinic acid riboside are authentic intracellular meta
268 we discovered that nicotinamide riboside and nicotinic acid riboside are biosynthetic precursors of N
269 se and nicotinamide riboside kinase and that nicotinic acid riboside bioavailability is increased by
270  for production of nicotinamide riboside and nicotinic acid riboside in cells.
271 leading to nicotinic acid mononucleotide and nicotinic acid riboside production are also uncovered th
272                  Finally, we show that yeast nicotinic acid riboside utilization largely depends on u
273 tracellular levels of nicotinamide riboside, nicotinic acid riboside, and other NAD(+) metabolites we
274                       Nicotinamide riboside, nicotinic acid riboside, O-ethylnicotinate riboside, O-m
275 alian purine nucleoside phosphorylase cleave nicotinic acid riboside, whereas the yeast phosphorylase
276 e yeast phosphorylase has little activity on nicotinic acid riboside.
277 nd potent agonist and allosteric enhancer of nicotinic acid's action, was the basis for most other co
278                         This defect prevents nicotinic acid secretion, which is the basis for the nia
279                                              Nicotinic acid significantly inhibited wild-type BMM che
280              For 1b, "inactive" pyridine and nicotinic acid speed up the demetalation in the presence
281                                          The nicotinic acid stacks between the re face of the FMN and
282 and colleagues proposed a mechanism in which nicotinic acid stimulates cholesterol mobilisation from
283                                           As nicotinic acid stimulates the GPCR GPR109A and Gi/Go pro
284  In a human cell line-based signaling assay, nicotinic acid stimulation led to pertussis toxin-sensit
285 nlipid-mediated anti-inflammatory effects of nicotinic acid such as direct enhancement of adiponectin
286 e somnogenic and thermoregulatory effects of nicotinic acid suggesting that they are mediated by the
287 icative L. pneumophila are treated with 5 mM nicotinic acid, the bacteria induce numerous transmissiv
288 g response but can antagonize the ability of nicotinic acid to elicit a flush response in vivo.
289 todecarboxylation of the corresponding 6-oxo nicotinic acid to furnish 2-pyridone.
290 e benefits likely result from the ability of nicotinic acid to inhibit lipolysis in adipocytes and th
291 ed function, the gene most highly induced by nicotinic acid treatment encodes a putative major facili
292 oreover, an additional 213 genes specific to nicotinic acid treatment were altered.
293                                      Whether nicotinic acid use becomes routine in the treatment of a
294                                              Nicotinic acid, used for atherosclerosis treatment, has
295 ction before and after a single oral dose of nicotinic acid using cardiac MRI to demonstrate contract
296 cted mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography.
297 onjugated with neuroactive carriers, namely, nicotinic acid, valproic acid, theophylline-7-acetic aci
298                  The average content of free nicotinic acid was 520.4 mg for immediate-release niacin
299          Yeast cells convert nicotinamide to nicotinic acid, while mammals lack the enzyme nicotinami
300                          Interactions of the nicotinic acid with backbone atoms indicate the structur

 
Page Top